The North Rackla Project
Source: Cantex Mine Development Corp.
  • Cantex Mine Development (CD) is releasing a new round of exploration results
  • Results are from drilling at the Main Zone of the company’s 100-per-cent-owned 14,077-hectare North Rackla claim block in the Yukon
  • Three out of five holes from the 2022 fall drill program extended the Main Zone mineralization 150 metres further to the northeast
  • One step-out hole intersected 23.5 metres of 20.46 grams per tonne of silver and 8.34 percent combined lead and zinc
  • Cantex Mine Development is up 17.65 percent, trading at $0.20 at 1:30 p.m. EST

Cantex Mine Development (CD) is releasing a new round of exploration results.

The results come from drilling of the Main Zone of the company’s 100-per-cent-owned 14,077-hectare North Rackla claim block in the Yukon.

Three out of five holes from the 2022 fall drill program extended the Main Zone mineralization 150 metres further to the northeast than had been previously identified, bringing the zone’s strike length to 2,300 metres.

One step-out hole intersected 23.5 metres of 20.46 grams per tonne of silver and 8.34 percent combined lead and zinc.

“Where lead or zinc values exceeded one percent, the Pb-OG62 or Zn-OG62 techniques were used. These have upper limits of 20 percent lead and 30 percent zinc, respectively. Samples with lead and zinc values over these limits were then analyzed by titration methods Pb-VOL70 and Zn-VOL50. Where silver samples exceeded 100 g/t, the Ag-OG62 technique was used, which has an upper limit of 1,500 g/t. The over limit analyses contributed to delays in receiving final assay results,” the British Columbia-based company said in a release Thursday.

Further lab analysis is pending.

Cantex Mine Development is up 17.65 percent, trading at $0.20 at 1:30 p.m. EST.


More From The Market Online

@ the Bell: TSX recovers and S&P hits fresh high

Energy shares led enough of a rally to overcome industrials and tech losses to push the TSX to a positive end on Tuesday.

Pathologists group accepts Telo Genomics’ test for rare blood cancer

The College of American Pathologists accepts the Telo Genomics' (TSXV:TELO) submission of a test for a rare blood cancer.

Theralase adds cancer immunotherapy to potential revenue streams

Theralase Technologies' (TSXV:TLT) lead drug candidate, Rutherrin, enhanced cancer immunotherapy in a pre-clinical setting.